医学
安慰剂
不利影响
临床试验
随机对照试验
疾病
双盲
外科
内科学
替代医学
病理
作者
Alessandro Sturiale,Lisa Fralleone,Danilo Cafaro,Gaetano Gallo,Luigi Brusciano,Felipe Celedón Porzio,Sreedhara VENKATARATNAIAH SETTY,Gabriele Naldini
出处
期刊:Minerva gastroenterology
[Edizioni Minerva Medica]
日期:2022-05-05
卷期号:68 (4)
被引量:1
标识
DOI:10.23736/s2724-5985.22.03173-4
摘要
BACKGROUND: Hemorrhoidal disease (HD) is one of the most common anorectal benign disorder affecting millions of people around the world. Grade I-II HD are generally treated with a conservative approach with topical products such as creams and ointments considered a safe and effective option to treat mild symptoms. The aim of the present study was to assess the safety and efficacy of a topical medical device (Lenoid™; International Health Science [IHS] - Biofarma Group, Mereto di Tomba, Udine, Italy) in patients affected by symptomatic HD.METHODS: This study is a randomized, double blind, placebo-controlled, 2-weeks clinical trial. Patients affected by I-II grade symptomatic HD were enrolled in the study and then randomly assigned to Lenoid™ arm (LA) or placebo arm (PA), respectively. Patients were evaluated before and after intervention through clinical examination and disease-specific questionnaires assessing symptoms such as pain, tenesmus, pruritus and anal discharge.RESULTS: A total of 68 patients were screened and 60 (30 in each group) were enrolled into the study. All patients belonging to LA showed a statistically significant improvement of each symptom after 7 and 14 days of treatment when compared to PA (P<0.001). Furthermore, subjective improvement of change in overall assessment of disease was observed in the LA but not in the PA. No serious adverse events were recorded.CONCLUSIONS: The tested product was found safe and effective in improving clinical signs and symptoms in patients with grade I-II HD.
科研通智能强力驱动
Strongly Powered by AbleSci AI